Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac

Diseases of the Colon and Rectum

Volumn 39, Issue 6, 1996, Pages 659-662

  Nugent, K P ^a   Spigelman, A D ^a,b   Phillips, R K S ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Carcinogenesis; Familial adenomatous polyposis; Prostaglandins

Indexed keywords

PROSTAGLANDIN E2; PROSTAGLANDIN F2; SULINDAC;

ADENOMATOUS POLYP; ARTICLE; CANCER RISK; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFECT; HUMAN; RANDOMIZED CONTROLLED TRIAL; TISSUE LEVEL;

ADENOMATOUS POLYPOSIS COLI; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; DINOPROST; DINOPROSTONE; HUMANS; REMISSION INDUCTION; SULINDAC;

EID: 0029954663     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02056946     Document Type: Article

References (34)

1. Pollard M, Luckert PH. Effect of indomethacin on intestinal tumours induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981;214:558-9.
2. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methyl nitrosurea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981;41:1954-7.
3. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
4. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study. Cancer Res 1988;48:4399-404.
5. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-8.
6. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
7. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. New Engl J Med 1991;325:1593-6.
8. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomised double blind placebo controlled clinical trial of the effect of Sulindac on duodenal and rectal polyposis and cell proliferation in familial adenomatous polyposis. Br J Surg 1993;80:1618-9.
9. Bennett A, Del-Tacca M, Stamford IF, Zebro T. Prostaglandins from tumours of human large bowel. Br J Cancer 1977;35:881-4.
10. Hubbard WC, Alley MC, McLemore TL, Boyd MR. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors. Cancer Res 1988;48:4770-5.
11. 2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 1990;33:840-5.
12. Neoptolemos JP, Husband D, Imray C, Rowley S, Lawson N. Arachidonic acid and docosahexaenoic acid are increased in human colorectal cancer. Gut 1991;32: 278-81.
13. Wahle KW. Dietary regulation of essential fatty acid metabolism and membrane phospholipid composition. Biochem Soc Trans 1990;18:775-8.
14. Goodlad RA, Madgwick AJ, Moffatt MR, Levin S, Allen JL, Wright NA. Prostaglandins and the gastric epithelium: effects of misoprostol on gastric epithelial cell proliferation in the dog. Gut 1989;30:316-21.
15. Goodlad RA, Mandir N, Levin S, Allen JL, Wright NA. Prostaglandins and the colonic epithelium: effects of misoprostol on crypt size, cell production, and cell migration in the dog. Gastroenterology 1991;101: 1229-34.
16. 2. Prostaglandins 1983;26:745-59.
17. 2. Prostaglandins 1984;27: 887-98.
18. Rozengurt E, Stroobant P, Waterfield MD, Deuel TF, Keehan M. Platelet-derived growth factor elicits cyclic AMP accumulation in Swiss 3T3 cells: role of prostaglandin production. Cell 1983;34:265-72.
19. Wickremasinghe RG. The role of prostaglandins in the regulation of cell proliferation. Prostaglandins Leukot Essent Fatty Acids 1988;31:171-9.
20. 2α. Proc Natl Acad Sci U S A 1975;72:2724-8.
21. Tilden AB, Balch CM. Indomethacin enhancement of immunocompetence in melanoma patients. Surgery 1981;90:77-84.
22. 2-mediated suppression of cellular immunity in colon cancer patients. Surgery 1984;95:71-7.
23. Pollock RE, Roth JA. Cancer-induced immunosuppression: implications for therapy? Semin Surg Oncol 1989; 5:414-9.
24. Knudsen PJ, Dinarello CA, Strom TB. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol + 1986;137: 3189-94.
25. Goodwin JS, Ceuppens JL. Prostaglandins, cellular immunity and cancer: prostaglandins and immunity. Boston: Martinus Nijhoff, 1985:1-34.
26. Unanue ER, Beller DI, Lu CY, Allen PM. Antigen presentation: comments on its regulation and mechanism. J Immunol 1984;132:1-34.
27. Stephan RN, Conrad PJ, Saizawa M, Dean RE, Chaudry IH. Prostglandin E2 depresses antigen-presenting cell function of peritoneal macrophages. J Surg Res 1988; 44:733-9.
28. Brem SS, Jensen HM, Gullino PM. Angiogensis as a marker of preneoplastic lesions of the human breast. Cancer 1978;41:239-44.
29. Maiorana A, Gullino PM. Acquistion of angiogenic capacity and neoplastic transformation in the rat mammary gland. Cancer Res 1978;38:4409-14.
30. Folkman J, Cotran R. Relation of vascular proliferation to tumor growth. Im Rev Exp Pathol 1976;16:207-48.
31. 1 and copper in angiogenesis. J Natl Cancer Inst 1982;69: 475-82.
32. Basu AK, Marnett LJ. Unequivocal demonstration that malondialdehyde is a mutagen. Carcinogenesis 1983;4: 331-3.
33. Marnett L. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
34. Basu AK, O'Hara SM, Valladier P, Stone K, Mois O, Marnett LJ. Identification of adducts formed by reaction of guanine nucleosides with malondialdehyde and structurally related aldehydes. Chem Res Toxicol 1988; 1:53-9.